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Abstract
Primary Sjögren’s syndrome (pSS) is an autoimmune disorder
characterized by specific pathological features. A hallmark of pSS
is B-cell hyperactivity as manifested by the production of auto-
antibodies, hypergammaglobulinemia, formation of ectopic lymphoid
structures within the inflamed tissues, and enhanced risk of B-cell
lymphoma. Changes in the distribution of peripheral B-cell subsets
and differences in post-recombination processes of immuno-
globulin variable region (IgV) gene usage are also characteristic
features of pSS. Comparison of B cells from the peripheral blood
and salivary glands of patients with pSS with regard to their
expression of the chemokine receptors CXCR4 and CXCR5, and
their migratory capacity towards the corresponding ligands,
CXCL12 and CXCL13, provide a mechanism for the prominent
accumulation of CXCR4+CXCR5+ memory B cells in the inflamed
glands. Glandular B cells expressing distinct features of IgV light
and heavy chain rearrangements, (re)circulating B cells with
increased mutations of cµ transcripts in both CD27– and CD27+
memory B-cell subsets, and enhanced frequencies of individual
peripheral B cells containing IgV heavy chain transcripts of multiple
isotypes indicate disordered selection and incomplete differen-
tiation processes of B cells in the inflamed tissues in pSS. This
may possibly be related to a lack of appropriate censoring
mechanisms or different B-cell activation pathways within the
ectopic lymphoid structures of the inflamed tissues. These findings
add to our understanding of the pathogenesis of this autoimmune
inflammatory disorder and may result in new therapeutic approaches.
Introduction
Primary Sjögren’s syndrome (pSS) is a chronic inflammatory
autoimmune disease with both organ-specific and systemic
manifestations [1-4]. pSS affects the salivary and lacrimal
glands preferentially but may frequently also involve other
exocrine glands, for example those of the respiratory tract,
gastrointestinal tract and skin [1-4]. pSS has therefore also
been termed ‘autoimmune exocrinopathy’ [1] or ‘autoimmune
epithelitis’ [4]. Focal infiltrates [5,6] of T and B lymphocytes,
dendritic cells (DCs) and macrophages [7-10] with
subsequent impairment of the salivary and lacrimal glandular
function are hallmarks of the disease and result clinically in
xerostomia and keratoconjunctivitis sicca. In addition to the
(glandular) organ-specific manifestations, there is a wide range
of accompanying clinical and laboratory manifestations,
emphasizing that pSS is a systemic autoimmune disorder [1-4].
The origin of pSS remains largely unknown. As with other
complex multigenic and multifactorial autoimmune diseases,
several infectious environmental factors, especially viral
agents such as Epstein–Barr virus, non-human immuno-
deficiency retroviruses and, more recently, coxsackieviruses
(namely the CVB4 and CVA13 strains) have been postulated
to be involved in priming or triggering pSS [11-14], on the
basis of a distinct genetic and hormonal background
[1-3,15]. Disturbed clearance from salivary gland epithelial
cells (SGECs) [5,16] may lead to glandular persistence of
viruses and to repeated lymphocytic sialadenitis with chronic
immune system stimulation [17]. However, it remains to be
determined whether viral infection of the affected glands is
primary or secondary to the development of autoimmunity in
pSS (for example Epstein–Barr virus infection [18]) or
whether different viruses (for example HTLV-1 [13], CVB4
and CVA13 [14]) may act as endemic triggers in distinct
human populations.
Although the process that underlies the cellular and humoral
autoimmune response in pSS is not known, it is well
established that both T and B lymphocytes are involved and
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that interactions of activated SGECs and endothelial cells
with the infiltrating lymphoid and dendritic cells contribute to
the perpetuation and progression of the disease as well as to
systemic lymphocyte derangements [1-4]. In this context,
dysregulation of the Th1/Th2 balance and chronic B-cell
hyperactivity are consistent and prominent immunoregulatory
abnormalities in pSS [1-3,19,20].
Characteristic features indicating B-cell disturbances in pSS
include circulating immune complexes, hypergammaglobu-
linemia, occurrence of organ-specific and organ nonspecific
autoantibodies (for example those against the Ro-SSA and/or
La-SSB autoantigens and rheumatoid factors), characteristic
disturbances of peripheral B-cell subsets, formation of
ectopic lymphoid tissue with germinal center (GC)-like
structures, oligoclonal B-cell proliferations and, finally, the
enhanced risk of developing B-cell lymphoma [1-3,21].
Recent studies [22-35] have broadened our understanding of
B-cell involvement in pSS by indicating that humoral markers
of B-cell hyperactivity and peripheral B-cell derangement
partly mirror the processes in the inflamed tissues, especially
in patients with pSS with detectable ectopic GC-like
structures. Similarly to pSS [27-35], ectopic lymphoid
structures have also been described in the target tissues of
several other autoimmune and non-autoimmune conditions
that are accompanied by B-cell disturbances and/or
enhanced lymphoma risk, for example rheumatoid arthritis
(RA) [21,36], systemic lupus erythematosus (SLE) [21,37],
autoimmune thyroiditis [38,39] and chronic infections such
as those by human immunodeficiency virus (HIV) [40,41],
hepatitis C virus [42,43] and Helicobacter pylori [44].
Delineation of common and diverse mechanisms that underlie
the B-cell disturbances and development of ectopic GC-like
structures in these disease entities should be important for
our understanding of their immunopathogenesis. Moreover,
this may also provide new strategies for B-cell-targeted
therapies in pSS, a disease with inadequate conventional
therapy. Taking current data as a basis, this review focuses
on the possible role of ectopically formed lymphoid tissue,
including GC-like structures, in B-cell disturbances and
autoimmune response in patients with pSS.
Lymphocytic sialadenitis and formation of
ectopic germinal-center-like structures
Chronic focal periductal lymphocytic sialadenitis is a hallmark
of pSS [5,6] and it has therefore been included in the
classification criteria of the disease [45,46]. Although
sequential analyses starting from early glandular tissue
infiltrates in pSS are not available, lymphocytic sialadenitis in
pSS is generally thought to be a stepwise process [1-4]. This
process may include a sequence of scattered tiny peri-
vascular lymphoid infiltrates, subsequent development of the
typical focal periductal lymphoid sialadenitis/formation of
ectopic GC-like structures and, eventually, the destruction
and replacement of the affected glandular tissue [8,27-35].
Notably, cytokine-mediate and/or autoantibody-mediated neuro-
endocrine glandular tissue dysfunction may occur before
glandular tissue damage is histologically evident [47,48].
The lymphoid tissue infiltrates in pSS contain T cells, B cells
and plasma cells, with a predominance of primed
CD4+(CD45RO+) T cells in early-stage disease [7-9]. It is
noteworthy that SEGCs are suggested to have a distinct
intrinsic or virus-activated status with disturbed apoptosis as
well as with the capability of promoting cell adhesion, to
function as antigen-presenting cells, and to co-stimulate
infiltrating CD4+ T cells [5,49]. Proinflammatory cytokines
(produced, for example, by the infiltrating CD4+ T cells and
dendritic cells) such as interferon-γ, IL-1β and TNF seem to
enhance the activation status of the SEGCs in a positive
feedback loop [5,50]. Activated SGECs may also express
CD40 protein, a molecule associated with B-cell and DC
activation [51,52], as well as B-cell activating factor (BAFF)
[53,54] and B-cell-attracting chemokines [29-31]. Moreover,
infiltrating CD4+ T cells and DCs may also locally produce a
broad variety of B-cell-targeted cytokines and survival factors,
including BAFF and APRIL (a proliferation-inducing ligand)
[50,55]. Thus, a tight interplay between activated SGECs,
infiltrating lymphocytes and DCs leads to the perpetuation
and progression of the disease, in an auto-amplifying loop.
B cells comprise about 20% of the lymphoid minor (labial)
salivary gland infiltrates in early-stage disease [7-9], but higher
degrees of lymphoid organization are associated with
progressive increases in the proportion of B cells and T-cell/B-
cell segregation, especially during the formation of ectopic
GC-like structures [27-33]. These ectopic ‘tertiary’ GC-like
structures of the inflamed tissues bear a histological resem-
blance to the GCs of secondary lymphoid organs. They
contain T-cell and B-cell aggregates with proliferating lympho-
cytes, a network of follicular DCs, and activated endothelial
cells with the morphology of high endothelial venules [37-33].
In healthy individuals, GCs are generated from primary B-cell
follicles of secondary lymphoid organs during T-cell-
dependent immune responses [56]. Lymphoid neogenesis
with or without the formation of ectopic GC-like structures in
chronic inflammatory diseases, such as pSS and RA, is a
complex process regulated by an array of cytokines, adhesion
molecules and chemokines, partly mimicking signals found in
normal lymphoid organogenesis [27-34,57-60]. However,
despite similarities to GCs of secondary lymphoid organs, the
function and potential pathogenetic role of ectopically formed
lymphoid structures within inflamed tissues remain unclear.
For example, in pSS, the following open questions remain
about the role of ectopically formed lymphoid tissue in B-cell
disturbances and autoimmune response: (1) Does the
formation of ectopic GC-like structures characterize a distinct
subgroup of patients? (2) Is the (auto)immune B-cell
response in ectopic lymphoid tissues dominated by T-cell-
dependent or T-cell-independent pathways? (3) Does ectopicPage 3 of 12
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lymphoid tissue represent the main priming site of auto-
reactive B cells? (4) Does ectopic lymphoid tissue formation
contribute to characteristic peripheral B-cell disturbances
caused by the underlying disease?
Diagnostic salivary gland biopsies detect
ectopic germinal center formation
Three distinct types of lymphoid microarchitecture can be
identified within the inflamed glands in pSS: unorganized
diffuse infiltrates, focal periductal T-cell and B-cell aggregates
lacking GC characteristics, and ectopic GC-like structures
[5,10,27-34]. Ectopic GC formation is associated with a
higher degree of lymphoid sialadenitis – that is, with a higher
focus score [6,33] – and GC-like structures often coincide
with focal periductal infiltrates [33]. Importantly, detection of
GC-like structures depends on the size or area of the
analyzed specimen [1]. At the time point of diagnostic biopsy
of the minor submucosal (labial) salivary glands, GC-like
structures have been documented in up to one-quarter of
patients with pSS [32,33]. By conventional routine
histological staining, for example with hematoxylin/eosin on
paraffin-embedded material, GC-like structures differ from
focal periductal infiltrates of mononuclear cells in having a
higher degree of lymphoid organization with a dark-appearing
mantle of densely packed cells and a lighter-appearing
center. Immunophenotyping reveals further characteristics of
well-ordered B cells, T cells, a network of follicular DCs and
activated endothelial cells in these ectopic GCs [27-34] and,
moreover, enhances the sensitivity of their detection [33].
However, it should be kept in mind that the time frame from
disease onset to diagnostic salivary gland biopsy may vary
markedly between different patients [2]. In this context, it
remains to be further elucidated whether the detection of
ectopic GC-like structures in a single biopsy reflects a
snapshot of a slowly progressive inflammatory disease, pSS,
or a subpopulation of patients with a more severe disease
and/or a distinct immune response. Recent studies have
shown a positive correlation between a high degree of
lymphoid tissue infiltration/ectopic GC formation in the minor
(labial) salivary glands and both the occurrence of
autoantibodies [32,61,62] and hypergammaglobulinemia
(elevated IgG levels) [33]. Moreover, a high degree of
lymphoid tissue infiltration or ectopic GC formation may be
related to an increased risk of extraglandular manifestations
and lymphoma [62-65]. At least, the detection of GC-like
structures in minor (labial) salivary gland biopsies may reflect
a progressive stage of disease in a distinct subset of patients.
The proportion of ‘ectopic GC-like structure-positive’ patients
with pSS may be somewhat underestimated by a single
biopsy of the minor (labial) salivary glands. In addition, minor
(labial) salivary glands are the most frequently investigated
but not the only tissue investigated for lymphocytic lesions in
pSS [66,67]. Importantly, the nature and intensity of immune
responses may vary between different affected tissues, for
example between different types of exocrine gland [66]. In
patients with pSS and recurrent or persistent swelling of the
major salivary glands, the lymphocytic lesions of the involved
glands often contain massive lymphoid infiltrates with
secondary lymph follicles and/or intraglandular lymph nodes
[63,64]. In this context, a recent study has documented a
strong correlation between the degree of lymphoid tissue
infiltration or formation of ectopic GC-like structures within
biopsies of the minor (labial) and major (parotid) glands of
patients with pSS [67]. Thus, the pattern of lymphoid
infiltrates of minor submucosal (labial) salivary glands seems
to be a marker of general inflammatory tissue involvement in
pSS, although further elucidation will be necessary to
determine whether the underlying immune processes may
vary between different types of inflamed tissue.
Characteristic distribution of peripheral B-cell
subsets
From the available data on the distribution of B-cell subsets in
chronic inflammatory rheumatic diseases, such as pSS, RA
and SLE, and in infectious diseases, there is increasing
evidence that diseases associated with immunological
hyperactivity can be characterized by unique features of B-
cell subset distribution [68,69]. Thus, the circulating B-cell
repertoire in peripheral blood may partly reflect complex
influences on differentiation, activation, selection, homing and
recirculation of B cells from a variety of immune compart-
ments, including the inflamed target tissues.
In this regard, the identification of CD27 as a marker of
memory B cells [70] and plasmablasts [71] made it possible
to characterize peripheral CD27– naive, CD27+ memory B
cells and CD27high plasmablasts/plasma cells. Interaction of
CD27 with its ligand on T cells, CD70, serves as a pathway
of differentiation of B cells into plasma cells [71,72].
Recently, homotypic interaction of CD27 and CD70
expressed by B cells was also reported to be sufficient for B-
cell differentiation, raising the possibility that B cells may be
able to regulate themselves by CD27–CD70 interactions
[72]. Analysis by various groups [22,24,70,71] indicates that
CD27– naive, CD27+ memory B cells and CD27high
plasmablasts/plasma cells exist in relatively stable relations in
the peripheral blood of healthy adults, although the frequency
of CD27+ memory B cells reflects the accumulation of
antigen experience of an individual that is, at least in part,
dependent on age [71]. In accordance, cord blood normally
does not contain CD27+ B cells [73]. In healthy adults,
CD27– naive B cells, CD27+ memory B cells and CD27high
plasmablasts/plasma cells comprise about 70%, 30% and
1%, respectively, of all CD19+ B cells in peripheral blood. An
increase in peripheral CD27high plasmablasts/plasma cells
has been shown after vaccination with bacterial antigens in
healthy individuals [74].
In pSS, immunophenotyping studies indicate characteristic
disturbances in the distribution of peripheral B-cell subsets,
Available online http://arthritis-research.com/content/9/4/218with a predominance of CD27– naive B cells and diminished
frequencies and absolute numbers of CD27+ memory B cells
[22-24], especially of the CD27+/IgM+, CD27+/IgD+ and
CD27+/CD5+ memory B-cell subsets [24]. These findings
clearly contrast with the pattern of B cells in peripheral blood
in healthy adults but also in patients with autoimmune
disorders that have to be distinguished from pSS such as
SLE, RA and secondary Sjögren’s syndrome (SS) [68,69]. In
comparison with either healthy subjects or patients with pSS,
patients with SLE have increased numbers of circulating
CD27+ memory B cells, reduced numbers of CD27– naive
B cells, and markedly increased numbers of CD27high plasma
cells that seemed to be related to lupus disease activity
and/or immunosuppressive therapy [75,76]. In contrast to
patients with pSS or RA, patients with SLE are frequently
B-cell lymphopenic [69]. Patients with RA show a similar
distribution of peripheral CD27– naive B cells and CD27+
memory B cells but a significantly enhanced CD27+/IgD+
memory subpopulation when compared with healthy donors
and patients with pSS [22,69]. The distribution of peripheral
B-cell subsets in patients with secondary SS are, at least,
dominated by those of the associated rheumatic disorder, for
example RA or SLE. Thus, the disturbances of the B-cell
subsets seem to be unique for each of the respective
diseases [68].
It is of potential interest that the status of the peripheral B-cell
subset distribution seems similar between pSS and HIV-
infected patients with predominantly CD27– naive B cells
[41,68]. In this context, CD4+ T cells are progressively
depleted in HIV infection, and patients with pSS often show a
mild CD4+ T lymphopenia. One interpretation of these obser-
vations may be that T-cell-dependent priming of B cells may
occur to a smaller degree in patients with pSS than in healthy
individuals and, especially, than in patients with SLE. In
contrast, diminished numbers of CD4+ T cells in peripheral
blood are found especially in patients with pSS showing
Ro/SSA positivity [77] and may reflect trafficking of primed
CD4+ T cells into the inflamed glands or GC-like structures
with subsequent autoantibody production [9,32]. Altered B-
cell differentiation and priming, shedding of surface CD27
molecules, accumulation of CD27+ memory B cells in
inflamed tissues and altered recirculation of B-cell subsets
from these sites may all contribute to disturbed B-cell
homeostasis in pSS [22-24].
Chemokines, ectopic germinal center
formation and accumulation of memory B cells
Support for the hypothesis that the decrease in CD27+
memory B cells in peripheral blood that occurs in pSS may
be partly related to their accumulation in the affected exocrine
glands comes from the combined immunophenotypic and
molecular studies analyzing B cells in peripheral blood and
salivary glands of patients with pSS [22-24,78]. These
studies revealed a polyclonal accumulation of CD27+
memory B cells and CD27high plasma cells in the inflamed
tissues, despite evidence of some clonally expanded B cells.
In more detail, peripheral blood B cells and glandular B cells
in patients with pSS used a similar polyclonal repertoire of
rearrangements of the immunoglobulin heavy-chain variable-
region gene (IgVH) [24,78]. However, when compared with
their peripheral blood counterparts, the vast majority of
glandular B cells expressed heavily mutated IgVH
rearrangements [24] along with significantly shorter heavy-
chain third complementarity-determining regions (HCDR3)
and a less frequent usage of the sixth heavy-chain joining
segment (JH6) [79], emphasizing the accumulation of memory
B cells. Thereby, enhanced influx and retention of particular
polyclonal memory B cells into the inflamed glands have been
suggested in patients with pSS, rather than the proliferation
of a few founder B cells entering the parotid GC-like
structures [24]. Notably, clonally related B cells have been
detected in the peripheral blood and the inflamed parotid
gland of a patient with pSS [79,80].
In addition, accumulation of memory B cells in the inflamed
salivary glands has been indicated by the analysis of
chemokine receptor–ligand interactions in pSS [26]. Inter-
actions of chemokines with their corresponding chemokine
receptors have been identified as having an important role in
lymphopoiesis, differentiation, homing, recirculation and
immune responses of lymphocytes under physiological and
pathological conditions, such as chronic inflammation and
ectopic GC formation [26,28-31,57-60]. The chemokine–
chemokine receptor pairs CXCL13 (BCA-1)–CXCR5 and
CXCL12 (SDF-1)–CXCR4 have been shown to be critically
involved in the homing of B cells to lymphoid follicles and in
the development of organized lymphoid follicles in healthy
individuals [60]. Mice deficient in the lymphoid-homing
chemokine receptors CXCR4 and CXCR5 lack normal
lymphoid organs [60,81]. In addition, studies in CXCL13
transgenic mice found that this chemokine, together with TNF
and lymphotoxin-β, is crucial in lymphoid organogenesis,
whereas the lymphotoxin-β ‘knockout mouse’ lacks the
formation of lymphoid structures [59,60]. Studies on RA
demonstrated that CXCL12 and CXCL13 [57-59] are also
involved in the formation of GC-like structures in the
rheumatoid synovium.
In pSS, recent studies reported that CXCL9 (Mig), CXCL10
(IP-10), CXCL12 (SDF-1), CXCL13 (BCA-1), CCL18
(PARC), CCL19 (ELC) and CCL21 (SLC) may all contribute
to lymphoid homing and the persistence of chronic inflam-
mation [28-31,59,60]. However, when compared with the
inflammatory process of nonspecific sialadenitis, salivary
glands in patients with pSS have been found to express a
unique profile of adhesion molecules, cytokines and
chemokines including a striking overexpression of the B-cell-
attracting chemokine CXCL13 (BCA-1) and, to a smaller
degree, CXCL12 (SDF-1) [28-31]. Accordingly, B cells
expressing the corresponding receptors for CXCL13
(BCA-1) and CXCL2 (SDF-1), CXCR5 and CXCR4,
Arthritis Research & Therapy    Vol 9 No 4 Hansen et al.
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patients with pSS [26,28,30]. Moreover, differential
expression of the chemokine receptors CXCR4 and CXCR5
but not of CXCR3, CCR6, CCR7 and CCR9 has been found
on peripheral blood B cells of patients with pSS in
comparison with those from healthy donors [26]. Thus,
CXCL12–CXCR4 and CXCL13–CXCR5 interactions have
been strongly suggested to be of special importance in B-cell
disturbances in pSS and may be closely associated with the
entire inflammatory process, the development of ectopic GC-
like structures as well as with peripheral B-cell disturbances
[26,28-31]. Overexpression of CXCL13 in inflamed glands
with consequent local retention of CXCR5-bearing B cells
[28,30] might also lead to reduced frequencies of peripheral
CD27+ memory B cells expressing lower levels of surface
CXCR5 than peripheral B cells of healthy donors [26].
Consistent with this, the vast majority of infiltrating CD27+
memory B cells in pSS salivary glands co-express CXCR5
with CXCR4, whereas there is a striking decrease in
CXCR4+CXCR5+ double-positive CD27+ memory B cells
but not CXCR4+CXCR5+ double-positive naive B cells in the
peripheral blood of patients with pSS [26]. In this context,
both in healthy individuals and in patients with pSS, CD27+
memory B cells show a higher intrinsic transmigratory
capacity to CXCL12 and CXCL13 than CD27– naive B cells
[26]. Thus, glandular coexpression of both CXCL12 and
CXCL13 [28-31] seems to direct this subpopulation of
peripheral CD27+ memory B cells preferentially into the
inflamed glands where it resides. Consistent with this,
residual circulating peripheral CD27+ memory B cells of
patients with pSS showed a diminished migratory response
to the corresponding ligands of CXCR4 and CXCR5, namely
CXCL12 and CXCL13, respectively [26]. This suggests that
memory B cells with less migratory capacity remain in the
blood as a result of the selective migration and retention of
CXCR4+CXCR5+ memory B cells into the inflamed glands
and thereby supports recent immunophenotypic and molecular
studies in pSS, indicating a preferential accumulation of
memory B cells in the salivary gland infiltrates [24,79].
Autoantibody responses, autoreactive B cells
and ectopic germinal centers
The production and persistence of autoantibodies in
autoimmune conditions are considered to occur because of
immune dysregulation with a resultant break in tolerance [82].
Despite intensive work on the characterization of auto-
antigens, B-cell biology, the cellular basis of autoantibody
production, the role of cytokines and chemokines, auto-
antibody-encoding immunoglobulin variable region (IgV)
genes and associations of certain autoantibody specificities
with particular MHC class II alleles, our understanding about
the origin and potential pathogenetic role of most of the
autoantibodies is still very limited.
However, autoantibodies in the patient’s serum and/or saliva
are a key manifestation of B-cell hyperactivity in pSS [1-3,
83,84]. Various autoantibody specificities have been reported
in patients with pSS, including antibodies against ubiquitous
or organ-nonspecific autoantigens (for example Ro/SSA,
La/SSB, α-Fodrin and the Fc fragment of IgG) and to mostly
organ-specific autoantigens (for example muscarinic M3
receptor and islet cell antigen 69) [1-3]. However, only a few
of them, such as anti-muscarinic M3 receptor antibodies,
have been implicated in contributing directly to the
impairment of salivary gland function in patients with pSS
[47]. It is more likely that most of these autoantibodies occur
in response to glandular tissue damage, apoptosis and/or the
expression of neoantigens such as cleaved La/SSB [85] and
Ro/SSA-hYRNA complexes on the blebs of apoptotic
glandular cells [86]. In this regard, 52 kDa Ro/SSA has
recently been characterized to function as an E3 ligase that
regulates proliferation and cell death and may thereby
contribute to the autoantigen load and induction of immune
responses in rheumatic disorders when there is increased 52
kDa Ro/SSA expression [87].
Altogether, the detection of both autoantigen-specific T and
B cells [88,89], evidence of antigen-driven clonal B-cell
expansions by analyzing the mutations of IgV gene rearrange-
ments [27], a linkage between local autoantibody production
and ectopic GC development [30,32] and the occurrence of
class-switched autoantibodies in the patient’s saliva [84] all
strongly indicate that T-cell-dependent immune responses
may occur to some extent in lymphoid tissue infiltrates,
especially in those containing ectopic GC-like structures. In
addition, the formation of autoantibodies in pSS seems to
occur independently from such structures, because
circulating autoantibodies are much more frequent than
ectopic ‘tertiary’ GCs in patients with pSS [32,33,67].
Of potential importance is a more recent study [35] that has
also claimed to detect marginal-zone (MZ)-like B cells within
the lymphoid tissue infiltrates of minor salivary glands of
patients with pSS. It is known that both hypermutation and Ig
class switch can also be mediated by T-cell-independent
pathways [90,91]. Hence, T-cell-independent immune res-
ponses may also occur within the inflamed tissues in pSS. In
this context, immune complexes, such as those containing
locally produced anti-Ro/SSA and nucleoprotein, may
activate dendritic and other cell types via Fc-γ receptors, Toll-
like receptors or B-cell receptors (BCRs) with rheumatoid
factor (RF) activity [92,93].
RF-expressing B cells seem to be intimately involved in the
pathogenesis of pSS, as has been indicated by the combined
results of several serological, molecular and epidemiological
studies [1,80,93-95]. Moreover, the subpopulation of RF-
expressing MZ-like B cells seems to be closely related to
lymphoma development in pSS [96-101]. Because MZ
B cells have been shown to be selected against autoreactivity
in healthy normals [102], the persistence of RF-expressing,
that is self-reactive, MZ-like B cells in pSS may reflect a
Available online http://arthritis-research.com/content/9/4/218
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lymphoid tissue that might permit the escape of MZ-like
B cells from BCR-mediated apoptosis, a normal physiological
peripheral ‘checkpoint’ against autoreactivity in secondary
lymphoid organs. In addition, the local production of IgG
immune complexes, for example of anti-Ro/SSA-nucleo-
protein complexes, may contribute to chronic activation and
proliferation of MZ-like B cells and, finally, to enhanced risk
for lymphoma development.
In this regard, BAFF and APRIL, two important factors that
can promote B-cell survival, have been strongly suggested to
be involved in both local and systemic autoimmunity in pSS,
including T-cell-independent immune responses [103,104].
Moreover, excess BAFF has been shown to be a potent
survival factor for mature B-cell malignancies [103]. Thus,
enhanced levels of BAFF have been demonstrated in
diseases such as pSS, SLE and RA, which are associated
with abnormal B-cell function and autoantibody production. In
particular, the highest BAFF levels have been found in
patients with pSS [53]. A recent study has shown a clear
anti-apoptotic effect of BAFF on B cells in peripheral blood
from patients with pSS that might lead to prolonged B-cell
survival in pSS [105]. Moreover, local expression of BAFF
has been found to be markedly enhanced in the inflamed
salivary glands in pSS. Locally expressed BAFF, for example
by glandular epithelial cells [54] and/or infiltrating T cells and
macrophages [55], may induce the accumulation of self-
reactive B cells by providing help to escape from BCR-
engaged apoptosis. Thus, local BAFF expression may be
central in the progression of the entire autoimmune process
by triggering B-cell survival and autoantibody production
[103,106]. Positive correlations between serum levels of
BAFF and APRIL with both the focus score of salivary glands
and serum IgG levels, especially in anti-Ro/anti-La-positive
patients, further suggest a possible role for BAFF and APRIL
in B-cell hyperactivity in pSS [33,34]. It is of potential
importance that BAFF together with BCR engagement
seems to be intimately involved in T-cell-independent B-cell
activation, including Ig class switch recombination via
transmembrane activator and CAML interactor (TACI), one of
the receptors for BAFF and APRIL [103,104]. Consistent
with this, studies in BAFF-transgenic mice revealed an
expansion of the MZ B-cell population and enhanced T-cell-
independent immune responses [107]. Although the degree of
T-cell-independent immune response in pSS remains unclear,
taken together these studies strongly suggest an important role
of BAFF excess in B-cell disturbances, autoantibody
production and possibly B-cell lymphomagenesis [103].
Autoantibody production may perpetuate the entire
inflammatory process as well as serving as an indicator of
immune dysregulation. Thus, autoantibodies in pSS also
seem to represent markers of disease progression and to
characterize a proportion of patients who are susceptible to a
more systemic involvement [108]. In patients with pSS, the
occurrence of circulating autoantibodies against the Ro/SSA
and La/SSB autoantigens, as well as elevated RF levels, is
correlated with the progressive stage of sialadenitis/formation
of ectopic lymphoid structures, systemic manifestations
and/or enhanced lymphoma risk [61,62,65,101,108]. However,
because stable levels of autoantibodies in serum are also
found in patients with pSS with late-stage disease, namely
with mostly atrophic exocrine glands, the generation of long-
lived plasma cells [109] or alternative sites for the ongoing
stimulation of autoreactive B cells in pSS may occur. In this
context, in addition to the salivary glands, autoreactive/
autoantibody-producing cells may also reside in ‘true’
lymphoid tissues of the secondary lymphoid organs and the
bone marrow, as demonstrated in the lymph nodes of sero-
positive MRL/lpr mice [110].
IgVH/L analyses indicate disturbed B-cell
selection in ectopic lymphoid tissues
As has been reviewed elsewhere [68], recent analyses have
provided no clear indication for inherited abnormalities in Ig VH,
Vκ and Vλ gene usage in patients with pSS in comparison with
healthy individuals. The most striking abnormalities found in
these studies were related to influences of selection; that is,
post-recombination processes. In B cells in peripheral blood,
the abnormalities included VL gene distribution of four Vλ
genes (2A2, 2B2, 2C and 7A), representing 56% of all
functional Vλ light chain rearrangements [111], and three Vκ
genes (L12, O12/O2 and B3) comprising 43% of all functional
VκJκ rearrangements [112]. In contrast, there were also
specific differences in the VL gene repertoire when B cells from
blood and from the parotid gland were compared [80]. B cells
from the parotid gland have been identified as a distinct
population showing accumulation, expansion and somatic
mutation of particular VL chain rearrangements, such as
VκA27–Jκ5, VκA19–Jκ2 and Vλ1C–Jλ2/3 in comparison with
peripheral B cells [80]. Together, these data are consistent
with the conclusion that positive selective processes and
clonal expansions shape a distinct VL gene repertoire of B cells
accumulated within the inflamed gland. Although the
corresponding VH repertoire was similar in the blood and in the
parotid, this analysis detected glandular accumulation of
memory B cells with significantly enhanced mutational
frequencies and shorter third HCDRs than their counterparts in
peripheral blood [24,79]. Collectively, this data set of VH/L gene
usage indicates positive selection and accumulation of memory
B cells expressing particular VL genes within the ectopic
lymphoid tissue in pSS [24,79,80]. In accord with these
results, earlier studies examining idiotype expression by
glandular B cells in pSS have also suggested that these cells
represent a selected population. B cells expressing RF-
associated cross-reactive idiotypes, in particular the light-chain
idiotype 17.109 (encoded by the VκA27/humkv325 gene) and
to a smaller degree the heavy-chain idiotypes G6, G8 and H1
(encoded by the VH1-69/DP-10 gene), are increased in the
salivary gland infiltrates of patients with pSS compared with
those with nonspecific sialadenitis [94,95].
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higher risk to develop B-cell non-Hodgkin lymphomas [21],
which emerge frequently within ectopic lymphoid tissues or
corresponding lymph nodes of the organs targeted by pSS
[64,96-101]. These lymphomas, frequently extranodal MZ
B-cell lymphomas [96-101], use remarkedly biased IgVH/L
gene repertoires with distinctive features of the third HCDR
that may often encode rheumatoid factors [96-98]. A recent
study [97] provided direct evidence that two cases of IgMκ-
expressing parotid gland B-cell non-Hodgkin lymphomas,
namely a small lymphocytic lymphoma and a MZ B-cell
lymphoma, developed in patients with pSS from mono-
specific RF-expressing B cells. More recently, (re)circulation
of two additional parotid gland B-cell clones along with the
lymphoma clone, all expressing RF-associated VH/L rearrange-
ments, have been found in a patient with pSS with extranodal
MZ B-cell lymphoma of the parotid gland [98]. Ongoing VH/L
mutations with an (auto)antigen-selected pattern in extranodal
MZ B-cell lymphomas in pSS strongly suggest that both
genesis and progression of these lymphomas are (auto)antigen-
selected processes [96,98,113]. Taken together, these data
implicate disturbed selection and (auto)antigen stimulation of
B cells within the ectopic lymphoid tissues in pSS that may
eventually contribute to the enhanced risk for lymphoma in
these patients [21].
(Re)circulating peripheral B cells exhibit
signs of abnormal differentiation
Amplification of mRNA by single-cell analysis allows the
evaluation of the transcriptome of individual cells and there-
fore provides the opportunity to gain an insight into the
variability of immunocompetent cells. By employing this
approach on IgVH expression and additional target mRNAs in
peripheral CD27– and CD27+ B cells from patients with pSS
[25], several abnormalities became apparent. Although the
distribution of VH and JH family members, the usage of
individual VH segments and the HCDR3 length were very
similar between healthy controls and patients with pSS,
markedly enhanced percentages of IgVH mRNA-positive
B cells were found in patients with pSS [25]. This difference
may reflect polyclonal B-cell hyperactivity [1-4] with
increased Ig mRNA levels in pSS, because mRNA expression
of housekeeping genes was comparable between patients
and controls by this analysis [25]. In addition, several
abnormalities suggest disturbed or incomplete B-cell differen-
tiation processes in pSS that contrast with the findings in
healthy subjects.
First, CD27– B cells from patients with pSS included a
notable proportion (about 17%) of memory-like B cells that
expressed IgVH rearrangements with two or more mutations
per VH segment [25]. The frequency of such CD27– memory-
type B cells detected at the single-cell mRNA level was in line
with previous genomic single-cell studies in patients with
pSS [24], whereas these cells occur infrequently among
CD27– B cells of healthy subjects [70]. CD27– memory-type
B cells may represent recirculating cells from secondary or
ectopically formed ‘tertiary’ lymphoid tissues with low-level,
transiently expressed or shed CD27 surface molecules. In
this regard, recent studies of patients with pSS have
suggested abnormal B-cell differentiation and activation
characterized by depressed percentages of circulating
CD27+ memory B cells [22-24], enhanced serum IgG levels
and elevated levels of soluble CD27 [23]. It is currently
unknown whether enhanced frequencies of (re)circulating
CD27– memory-like B cells are correlated with a higher
degree of tissue involvement or ectopic GC formation.
However, it should be noted that the mutational frequencies
of CD27– B-cell-derived mutated IgVH rearrangements in
pSS were significantly lower than that of their CD27+
memory B-cell-derived counterparts [24,25]. This may
possibly reflect T-cell-independent B-cell activation [90,91],
for example via Toll-like receptors and/or BAFF–TACI
interaction [92,104].
Second, the peripheral CD27+ memory B-cell-derived IgVH
transcripts from patients with pSS differed from those in
healthy controls in having significantly enhanced mutational
frequencies, including an abnormal isotype-specific order in
mutational frequencies [25]. In particular, in patients with
pSS, the CD27+ memory B-cell-derived cµ transcripts were
found to be significantly more mutated than the corres-
ponding  γ and  α chain transcripts. If these findings are
combined with those from previous immunophenotyping and
molecular studies [24,80,94-98], the populations of IgM (cµ)-
expressing memory B cells and memory-type B cells seem to
be closely involved in both B-cell disturbances and malignant
complications in pSS.
Finally, more than half of individual peripheral CD27+ memory
B cells from patients with pSS have been found to express
spliced IgVH mRNA transcripts of more than one of the heavy-
chain isotypes µ, γ or α simultaneously [25]. The frequency of
these B cells was markedly enhanced in patients with pSS
compared with healthy controls. In particular, triple (µ, γ and α
chain transcript) positive B cells were found only in patients
with pSS. The expression of multiple Ig heavy-chain isotypes
in individual peripheral B cells occurs at the mRNA level but
not at the protein level, because no multiple heavy-chain-
positive B cells could be detected by flow cytometric surface
staining for their respective isotypes, IgM, IgG and IgA [25].
Because these multiple-positive (class-switching) cells
lacked mRNA expression of two GC B-cell markers, Bcl-6
and activation-induced cytidine deaminase [114], they most
probably represent altered CD27+ memory B cells but not
GC B cells. Thus, no circulating CD38++ IgD– GC B cells
have been detected in the peripheral blood by flow
cytometric analysis, either in patients with pSS or in healthy
controls [22].
These differences in the frequency of peripheral class-
switching CD27+ B cells as well as the different imprints of
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with pSS may reflect hyperactivation, altered differentiation
and/or recirculation from secondary or ectopic (tertiary)
lymphoid tissues of pSS B cells. Isotype class switching is a
complex multistep process that requires close collaboration
between surface IgM-expressing B cells and CD4+ helper
T cells in the environment of secondary lymphoid tissues
[56,60], but it may also be induced by T-cell-independent
pathways via Toll-like receptor engagement or BAFF–TACI
interaction [90-92,103]. However, in both pathways, cellular
collaboration depends on the binding and subsequent
processing of antigen, interaction via complementary pairs of
adhesion molecules, and a certain milieu of immuno-
modulatory cytokines, alterations of which may contribute to
abnormalities in pSS [59,60]. One explanation for class-
switching memory B cells in the peripheral blood in pSS
might be that they had incomplete differentiation processes,
possibly in the ectopic (tertiary) lymphoid structures of the
inflamed tissues. Thus, multiple Ig transcript-positive (class-
switching) CD27+ B cells have been recently detected in
focal minor (labial) salivary gland infiltrates of patients with
pSS (A Hansen, K Reiter, K Kemnitz, PE Lipsky, T Dörner,
unpublished work). These cells might therefore occur in the
peripheral blood immediately after they switched and still had
residual transcripts for pre-switch Ig isotypes, thereby
reflecting altered immune activation and/or incomplete
differentiation processes. Abnormal expression of
immunoregulatory Th2 cytokines, such as IL-2, IL-4 and IL-10
[19,20,32,34,115], and local excess BAFF [53-55] may
contribute to altered B-cell activation and class switching
within the inflamed glands. It remains to be determined
whether a molecular defect in metabolizing Ig mRNA or
enhanced B-cell turnover in pSS also contributes to the
alterations in Ig mRNA level.
Conclusions
Characteristic disturbances of peripheral B-cell homeostasis
with depletion of CD27+ memory B cells in the peripheral
blood and evidence for the accumulation and retention of
antigen-experienced B cells in the inflamed tissues, together
with new findings on the role of chemokines and chemokine
receptors, provide new insight into the immunopathogenesis
of pSS. Although the present data indicate that there is no
major molecular abnormality in generating the IgV heavy-
chain and light-chain repertoire in patients with pSS,
processes of chronic B-cell activation, disordered selection
and differentiation apparently lead to remarkable differences
in V gene usage by pSS B cells. Ectopically formed lymphoid
structures within patients’ inflamed tissues seem to be
closely involved in these abnormalities. Selective influences
after encountering (auto)antigen lead to preferential changes
in VL gene usage and in the length of the CDR3 of VH
rearrangements of glandular B cells in pSS. One possible
explanation is that fine tuning of the antigen-binding pocket
exerts a preferential influence on the VHCDR3 and Ig VL
chains. Accumulation and disordered selection of (auto)antigen-
experienced B cells in the ‘niche’ of ectopically formed
lymphoid tissues may result in abnormal activation and
differentiation of B cells, local autoantibody production,
stimulation of RF-expressing B cells and potential malignant
transformation in pSS (Figure 1). Circulating peripheral B
cells from patients with pSS partly reflect these processes
within the ectopic ‘tertiary’ and/or secondary lymphoid
tissues. It is noteworthy that the combined results of recent
studies indicate that detectable GC-like structures within
these ectopic lymphoid tissues represent a progressive stage
of disease or a higher degree of focal lymphoid sialadenitis in
a subgroup of patients. However, GC-like structures seem
not to be essential for B-cell disturbances in pSS. This is in
line with the assumption that an important part of abnormal B-
cell activation, selection and differentiation in pSS may be
triggered by T-cell-independent pathways (Figure 1).
Although these disturbances need further delineation, the
available data may provide paths to understanding the
underlying pathogenetic mechanisms of this entity. In
particular, the awareness of the involvement of B cells in the
immunopathology of pSS has aroused great interest in
developing improved therapies, such as B-cell depletion by a
chimeric anti-CD20 antibody [116] or B-cell modulation by
an anti-CD22 antibody [117].
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Figure 1
Hypothetical scheme of B-cell differentiation pathways in ectopic
lymphoid tissues in primary Sjögren’s syndrome. Preactivated peripheral
B cells are recruited by chemokines into the microenvironment of
chronically inflamed tissues. This microenvironment represents a ‘niche’
where B cells may escape from peripheral check points against
autoreactivity but are abnormally stimulated, proliferate and incompletely
differentiate via T-cell-dependent or T-cell-independent pathways into
memory B cells and plasma cells. Rheumatoid factor-expressing B cells
may be abnormally stimulated by local BAFF excess and locally
secreted (auto)antibodies. Abnormal stimulation and impaired censoring
mechanisms enhance the risk for malignant transformation of B cells.
Emigration and recirculation of B cells that had incomplete
differentiation processes contribute to peripheral B-cell disturbances.
EC, epithelial cell; FDC, follicular dendritic cell; PC, plasma cell; BAFF,
B-cell activating factor; Ig, immunoglobulin.Competing interests
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